Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Position Trimmed by Caxton Corp

Caxton Corp cut its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 60.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,015,157 shares of the company's stock after selling 3,098,191 shares during the period. Xeris Biopharma comprises approximately 41.1% of Caxton Corp's portfolio, making the stock its largest position. Caxton Corp owned 1.35% of Xeris Biopharma worth $6,831,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in XERS. NewEdge Advisors LLC acquired a new position in shares of Xeris Biopharma in the fourth quarter worth approximately $34,000. R Squared Ltd bought a new stake in shares of Xeris Biopharma in the 4th quarter valued at $42,000. Cibc World Markets Corp acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth $44,000. Raymond James Financial Inc. bought a new position in Xeris Biopharma during the fourth quarter worth $45,000. Finally, Aquatic Capital Management LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at $50,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 6.47% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on XERS. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group restated a "buy" rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Leerink Partners lifted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Oppenheimer increased their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday. Finally, Piper Sandler restated a "neutral" rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Trading Down 2.5 %

NASDAQ XERS traded down $0.13 during mid-day trading on Friday, hitting $5.03. The company's stock had a trading volume of 2,547,354 shares, compared to its average volume of 1,935,486. The firm has a market capitalization of $786.62 million, a price-to-earnings ratio of -11.18 and a beta of 1.10. The company's 50 day simple moving average is $4.66 and its 200 day simple moving average is $3.85. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. As a group, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.